

# Christian Pagnoux

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/616363/publications.pdf>

Version: 2024-02-01

166  
papers

11,264  
citations

61984

43  
h-index

30087

103  
g-index

169  
all docs

169  
docs citations

169  
times ranked

5857  
citing authors

#	ARTICLE	IF	CITATIONS
1	Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis. <i>New England Journal of Medicine</i> , 2014, 371, 1771-1780.	27.0	842
2	The Five-Factor Score Revisited. <i>Medicine (United States)</i> , 2011, 90, 19-27.	1.0	716
3	Eosinophilic granulomatosis with polyangiitis (Churgâ€“Strauss): Clinical characteristics and longâ€“term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. <i>Arthritis and Rheumatism</i> , 2013, 65, 270-281.	6.7	670
4	Azathioprine or Methotrexate Maintenance for ANCA-Associated Vasculitis. <i>New England Journal of Medicine</i> , 2008, 359, 2790-2803.	27.0	603
5	Antineutrophil Cytoplasmic Antibodies and the Churgâ€“Strauss Syndrome. <i>Annals of Internal Medicine</i> , 2005, 143, 632.	3.9	592
6	Mycophenolate Mofetil vs Azathioprine for Remission Maintenance in Antineutrophil Cytoplasmic Antibodyâ€“Associated Vasculitis. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 2381.	7.4	524
7	Clinical features and outcomes in 348 patients with polyarteritis nodosa: A systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French vasculitis study group database. <i>Arthritis and Rheumatism</i> , 2010, 62, 616-626.	6.7	483
8	Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. <i>New England Journal of Medicine</i> , 2020, 382, 622-631.	27.0	465
9	Hepatitis B Virus-Associated Polyarteritis Nodosa. <i>Medicine (United States)</i> , 2005, 84, 313-322.	1.0	371
10	Eosinophilic granulomatosis with polyangiitis (Churgâ€“Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. <i>European Journal of Internal Medicine</i> , 2015, 26, 545-553.	2.2	371
11	Presentation and Outcome of Gastrointestinal Involvement in Systemic Necrotizing Vasculitides. <i>Medicine (United States)</i> , 2005, 84, 115-128.	1.0	332
12	A Randomized, Doubleâ€“Blind Trial of Abatacept (CTLAâ€“4Ig) for the Treatment of Giant Cell Arteritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 837-845.	5.6	271
13	Churg-Strauss syndrome with poor-prognosis factors: A prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. <i>Arthritis and Rheumatism</i> , 2007, 57, 686-693.	6.7	243
14	Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibodyâ€“associated smallâ€“vessel vasculitis: Comparison of two independent cohorts. <i>Arthritis and Rheumatism</i> , 2008, 58, 2908-2918.	6.7	231
15	Churgâ€“Strauss syndrome. <i>Current Opinion in Rheumatology</i> , 2007, 19, 25-32.	4.3	199
16	Treatment of polyarteritis nodosa and microscopic polyangiitis without poorâ€“prognosis factors: A prospective randomized study of one hundred twentyâ€“four patients. <i>Arthritis and Rheumatism</i> , 2010, 62, 1186-1197.	6.7	179
17	Long-term outcomes of 118 patients with eosinophilic granulomatosis with polyangiitis (Churgâ€“Strauss syndrome) enrolled in two prospective trials. <i>Journal of Autoimmunity</i> , 2013, 43, 60-69.	6.5	168
18	Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: Results of a multicenter, prospective, openâ€“label study of twentyâ€“two patients. <i>Arthritis and Rheumatism</i> , 2008, 58, 308-317.	6.7	163

#	ARTICLE	IF	CITATIONS
19	Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1662-1668.	0.9	159
20	Treatment of Systemic Necrotizing Vasculitides in Patients Aged Sixty-Five Years or Older: Results of a Multicenter, Open-Label, Randomized Controlled Trial of Corticosteroid and Cyclophosphamide-Based Induction Therapy. <i>Arthritis and Rheumatology</i> , 2015, 67, 1117-1127.	5.6	150
21	Revisiting the systemic vasculitis in eosinophilic granulomatosis with polyangiitis (Churg-Strauss). <i>Autoimmunity Reviews</i> , 2017, 16, 1-9.	5.8	140
22	Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1150-1156.	0.9	139
23	A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Takayasu Arteritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 846-853.	5.6	131
24	Identification of Functional and Expression Polymorphisms Associated With Risk for Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2017, 69, 1054-1066.	5.6	130
25	Updates in ANCA-associated vasculitis. <i>European Journal of Rheumatology</i> , 2016, 3, 122-133.	0.6	125
26	Adding Azathioprine to Remission-Induction Glucocorticoids for Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss), Microscopic Polyangiitis, or Polyarteritis Nodosa Without Poor Prognosis Factors. <i>Arthritis and Rheumatology</i> , 2017, 69, 2175-2186.	5.6	117
27	Vasculitis in patients with inflammatory bowel diseases: A study of 32 patients and systematic review of the literature. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 45, 475-482.	3.4	109
28	Churg-Strauss syndrome: evidence for disease subtypes?. <i>Current Opinion in Rheumatology</i> , 2010, 22, 21-28.	4.3	103
29	Long-Term Outcomes Among Participants in the WEGENT Trial of Remission-Maintenance Therapy for Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis. <i>Arthritis and Rheumatology</i> , 2016, 68, 690-701.	5.6	101
30	Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1243-1249.	0.9	93
31	High-Resolution Magnetic Resonance Imaging of Scalp Arteries for the Diagnosis of Giant Cell Arteritis: Results of a Prospective Cohort Study. <i>Arthritis and Rheumatology</i> , 2017, 69, 161-168.	5.6	78
32	Long-term follow-up of a randomized trial on 118 patients with polyarteritis nodosa or microscopic polyangiitis without poor-prognosis factors. <i>Autoimmunity Reviews</i> , 2014, 13, 197-205.	5.8	77
33	Patterns of Arterial Disease in Takayasu Arteritis and Giant Cell Arteritis. <i>Arthritis Care and Research</i> , 2020, 72, 1615-1624.	3.4	77
34	Peripheral neuropathy in systemic vasculitides. <i>Current Opinion in Rheumatology</i> , 2005, 17, 41-48.	4.3	70
35	Predictors at diagnosis of a first Wegener's granulomatosis relapse after obtaining complete remission. <i>Rheumatology</i> , 2010, 49, 2181-2190.	1.9	66
36	CanVasc Recommendations for the Management of Antineutrophil Cytoplasm Antibody-associated Vasculitides. <i>Journal of Rheumatology</i> , 2016, 43, 97-120.	2.0	66

#	ARTICLE	IF	CITATIONS
37	Adjunctive Treatment With Avacopan, an Oral C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>ACR Open Rheumatology</i> , 2020, 2, 662-671.	2.1	64
38	Pregnancies in systemic necrotizing vasculitides: report on 12 women and their 20 pregnancies. <i>Rheumatology</i> , 2011, 50, 953-961.	1.9	62
39	Childhood Takayasu arteritis: disease course and response to therapy. <i>Arthritis Research and Therapy</i> , 2017, 19, 255.	3.5	54
40	Tracheobronchial Stenoses in Granulomatosis With Polyangiitis (Wegener's). <i>Medicine (United Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 62)</i>	1.0	53
41	Value of commonly measured laboratory tests as biomarkers of disease activity and predictors of relapse in eosinophilic granulomatosis with polyangiitis. <i>Rheumatology</i> , 2015, 54, 1351-1359.	1.9	52
42	Severe Intracranial Involvement in Giant Cell Arteritis: 5 Cases and Literature Review. <i>Journal of Rheumatology</i> , 2016, 43, 648-656.	2.0	51
43	Non-glucocorticoid drugs for the treatment of Takayasu's arteritis: A systematic review and meta-analysis. <i>Autoimmunity Reviews</i> , 2018, 17, 683-693.	5.8	50
44	Brief Report: Childhood-Onset Systemic Necrotizing Vasculitides: Long-Term Data From the French Vasculitis Study Group Registry. <i>Arthritis and Rheumatology</i> , 2015, 67, 1959-1965.	5.6	47
45	Childhood- versus adult-onset ANCA-associated vasculitides: A nested, matched case-control study from the French Vasculitis Study Group Registry. <i>Autoimmunity Reviews</i> , 2018, 17, 108-114.	5.8	42
46	Emergence of severe spondyloarthropathy-related enthesal pathology following successful vedolizumab therapy for inflammatory bowel disease. <i>Rheumatology</i> , 2019, 58, 963-968.	1.9	42
47	Comparisons of Guidelines and Recommendations on Managing Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Kidney International Reports</i> , 2018, 3, 1039-1049.	0.8	41
48	Mortality in systemic necrotizing vasculitides: A retrospective analysis of the French Vasculitis Study Group registry. <i>Autoimmunity Reviews</i> , 2018, 17, 653-659.	5.8	40
49	Presentation and Disease Course of Childhood-Onset Versus Adult-Onset Takayasu Arteritis. <i>Arthritis and Rheumatology</i> , 2019, 71, 315-323.	5.6	38
50	Subglottic stenosis and endobronchial disease in granulomatosis with polyangiitis. <i>Rheumatology</i> , 2019, 58, 2203-2211.	1.9	37
51	Wegener's Granulomatosis Strictly and Persistently Localized to One Organ Is Rare: Assessment of 16 Patients from the French Vasculitis Study Group Database. <i>Journal of Rheumatology</i> , 2011, 38, 475-478.	2.0	36
52	Fertility and pregnancy in vasculitis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2013, 27, 79-94.	3.3	36
53	When Should Immunosuppressants Be Prescribed to Treat Systemic Vasculitides?. <i>Internal Medicine</i> , 2003, 42, 313-317.	0.7	35
54	Non-severe eosinophilic granulomatosis with polyangiitis: long-term outcomes after remission-induction trial. <i>Rheumatology</i> , 2019, 58, 2107-2116.	1.9	33

#	ARTICLE	IF	CITATIONS
55	The Role of Biological Agents in the Management of Large Vessel Vasculitis (LVV): A Systematic Review and Meta-Analysis. PLoS ONE, 2014, 9, e115026.	2.5	31
56	A small n sequential multiple assignment randomized trial design for use in rare disease research. Contemporary Clinical Trials, 2016, 46, 48-51.	1.8	31
57	Churg-Strauss syndrome: evolving concepts. Discovery Medicine, 2010, 9, 243-52.	0.5	29
58	Diagnosis and management of <scp>ADA</scp>2 deficient polyarteritis nodosa. International Journal of Rheumatic Diseases, 2019, 22, 69-77.	1.9	28
59	Gastrointestinal aspects of vasculitides. Nature Reviews Gastroenterology and Hepatology, 2017, 14, 185-194.	17.8	27
60	CanVasc Consensus Recommendations for the Management of Antineutrophil Cytoplasm Antibody-associated Vasculitis: 2020 Update. Journal of Rheumatology, 2021, 48, 555-566.	2.0	27
61	Reply to: Importance of immunisation of elderly subjects before immunosuppressive treatment. Clinical and Experimental Rheumatology, 2016, 34, S21.	0.8	26
62	Atherosclerosis in ANCA-Associated Vasculitides. Annals of the New York Academy of Sciences, 2007, 1107, 11-21.	3.8	25
63	Non-biologic remission maintenance therapy in adult patients with ANCA-associated vasculitis: A systematic review and network meta-analysis. Joint Bone Spine, 2014, 81, 337-341.	1.6	25
64	Patterns of clinical presentation in Takayasu's arteritis. Seminars in Arthritis and Rheumatism, 2020, 50, 576-581.	3.4	25
65	Plasma exchange for systemic lupus erythematosus. Transfusion and Apheresis Science, 2007, 36, 187-193.	1.0	24
66	Experience With Direct-to-Patient Recruitment for Enrollment Into a Clinical Trial in a Rare Disease: A Web-Based Study. Journal of Medical Internet Research, 2017, 19, e50.	4.3	24
67	Vasculitis of the upper airways. Swiss Medical Weekly, 2012, 142, w13541.	1.6	24
68	Therapeutic Strategies for Systemic Necrotizing Vasculitides. Allergology International, 2007, 56, 105-111.	3.3	23
69	Granulomatosis with polyangiitis: Study of 795 patients from the French Vasculitis Study Group registry. Seminars in Arthritis and Rheumatism, 2021, 51, 339-346.	3.4	22
70	Extraocular manifestations of birdshot chorioretinopathy in 118 French patients. Presse Medicale, 2010, 39, e97-e102.	1.9	21
71	Clinical Manifestations and Long-term Outcomes of Eosinophilic Granulomatosis With Polyangiitis in North America. ACR Open Rheumatology, 2021, 3, 404-412.	2.1	21
72	Evaluation of Potential Serum Biomarkers of Disease Activity in Diverse Forms of Vasculitis. Journal of Rheumatology, 2020, 47, 1001-1010.	2.0	20

#	ARTICLE	IF	CITATIONS
73	Management of cutaneous vasculitis. <i>Presse Medicale</i> , 2020, 49, 104033.	1.9	20
74	Pregnancy Outcomes in Systemic Vasculitides. <i>Current Rheumatology Reports</i> , 2020, 22, 63.	4.7	20
75	Encrusting Cystitis Due to <i>Corynebacterium urealyticum</i> in a Patient with ANCA-Associated Vasculitis: Case Report and Review of the Literature. <i>Seminars in Arthritis and Rheumatism</i> , 2011, 41, 297-300.	3.4	18
76	Treatment of granulomatosis with polyangiitis (Wegener's). <i>Expert Review of Clinical Immunology</i> , 2015, 11, 339-348.	3.0	18
77	How can patient care be improved beyond medical treatment?. <i>Best Practice and Research in Clinical Rheumatology</i> , 2005, 19, 337-344.	3.3	17
78	Concordance of Time-of-Flight MRA and Digital Subtraction Angiography in Adult Primary Central Nervous System Vasculitis. <i>American Journal of Neuroradiology</i> , 2017, 38, 1917-1922.	2.4	17
79	Use and reporting of outcome measures in randomized trials for anti-neutrophil cytoplasmic antibody-associated vasculitis: a systematic literature review. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1314-1325.	3.4	17
80	Comparison of Two Rituximab Induction Regimens for Antineutrophil Cytoplasm Antibody-Associated Vasculitis: Systematic Review and Meta-Analysis. <i>ACR Open Rheumatology</i> , 2021, 3, 484-494.	2.1	17
81	Indication for plasma exchange for systemic necrotizing vasculidities. <i>Transfusion and Apheresis Science</i> , 2007, 36, 179-185.	1.0	16
82	Optimal therapy and prospects for new medicines in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). <i>Expert Review of Clinical Immunology</i> , 2016, 12, 1059-1067.	3.0	16
83	Pulmonary involvement in primary systemic vasculitides. <i>Rheumatology</i> , 2021, 61, 319-330.	1.9	16
84	Characteristics, prognosis, and outcomes of cutaneous ischemia and gangrene in systemic necrotizing vasculitides: A retrospective multicenter study. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 43, 681-688.	3.4	15
85	Editorial: Classifying Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitides According to ANCA Type or Phenotypic Diagnosis: Salt or Pepper?. <i>Arthritis and Rheumatology</i> , 2016, 68, 2837-2840.	5.6	15
86	Pregnancy outcomes in women with primary systemic vasculitis: a retrospective study. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2021, 34, 1-7.	1.5	15
87	Infection-associated vasculitides. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 109-115.	1.9	15
88	Prevalence and management of cardiovascular risk factors in ANCA-associated vasculitis. <i>Rheumatology</i> , 2019, 58, 2333-2335.	1.9	14
89	Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 617-630.	3.1	14
90	Protocol for a randomized multicenter study for isolated skin vasculitis (ARAMIS) comparing the efficacy of three drugs: azathioprine, colchicine, and dapsone. <i>Trials</i> , 2020, 21, 362.	1.6	14

#	ARTICLE	IF	CITATIONS
91	Efficacy of leflunomide in the treatment of vasculitis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 114-118.	0.8	14
92	CanVasc Recommendations for the Management of Antineutrophil Cytoplasm Antibody (ANCA)-Associated Vasculitides – Executive Summary. <i>Canadian Journal of Kidney Health and Disease</i> , 2015, 2, 78.	1.1	12
93	Prognostic Significance of Cavitory Lung Nodules in Granulomatosis With Polyangiitis (Wegener's): A Clinical Imaging Study of 225 Patients. <i>Arthritis Care and Research</i> , 2018, 70, 1082-1089.	3.4	12
94	Predictors of fatal and non-fatal cardiovascular events in ANCA-associated vasculitis: Data from the Toronto CanVasc cohort. <i>Joint Bone Spine</i> , 2020, 87, 221-224.	1.6	12
95	CNS Involvement in Acute Posterior Multifocal Placoid Pigment Epitheliopathy. <i>Canadian Journal of Neurological Sciences</i> , 2011, 38, 526-528.	0.5	11
96	Eosinophilic granulomatosis with polyangiitis (formerly Churg's/Strauss syndrome): where are we now?. <i>European Respiratory Journal</i> , 2015, 46, 1255-1258.	6.7	11
97	Long-term outcomes of patients with Takayasu arteritis and renal artery involvement: a cohort study. <i>Rheumatology Advances in Practice</i> , 2018, 2, rky026.	0.7	11
98	Long-term use and remission of granulomatosis with polyangiitis with the oral C5a receptor inhibitor avacopan. <i>BMJ Case Reports</i> , 2020, 13, e236236.	0.5	11
99	Update in the Management of ANCA-Associated Vasculitis: Recent Developments and Future Perspectives. <i>International Journal of Rheumatology</i> , 2021, 2021, 1-14.	1.6	10
100	Avacopan for the treatment of ANCA-associated vasculitis. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 717-726.	3.0	10
101	Churg-Strauss Syndrome and Leukotriene-Modifying Agents. <i>Clinical Pulmonary Medicine</i> , 2004, 11, 349-354.	0.3	9
102	Remittent non-destructive polysynovitis in P-ANCA-positive vasculitis patients with anti-CCP antibodies. <i>Joint Bone Spine</i> , 2010, 77, 604-607.	1.6	9
103	Conventional and biological immunosuppressants in vasculitis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2018, 32, 94-111.	3.3	9
104	Impact of diabetes, angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker use, and statin use on presentation and outcomes in patients with giant cell arteritis. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 1233-1239.	1.9	9
105	Comparative study of granulomatosis with polyangiitis subsets according to ANCA status: data from the French Vasculitis Study Group Registry. <i>RMD Open</i> , 2022, 8, e002160.	3.8	9
106	Pharmacological approaches to CNS vasculitis: where are we at now?. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 109-116.	3.1	8
107	Sustained Remission of Granulomatosis With Polyangiitis After Discontinuation of Glucocorticoids and Immunosuppressant Therapy: Data From the French Vasculitis Study Group Registry. <i>Arthritis and Rheumatology</i> , 2021, 73, 641-650.	5.6	8
108	Patients of 75 years and over with ANCA-associated vasculitis have a lower relapse risk than younger patients: A multicentre cohort study. <i>Journal of Internal Medicine</i> , 2021, , .	6.0	8



#	ARTICLE	IF	CITATIONS
109	Updates in ANCA-associated vasculitis. , 2022, 9, 153-166.		8
110	Do vaccinations affect the clinical course of systemic necrotising vasculitis? A prospective observational web-based study. Clinical and Experimental Rheumatology, 2016, 34, S89-92.	0.8	8
111	Letter by de Boysson and Pagnoux Regarding Article, "Diagnostic Yield and Safety of Brain Biopsy for Suspected Primary Central Nervous System Angiitis" Stroke, 2016, 47, e256.	2.0	7
112	Development of Canadian Recommendations for the Management of ANCA-Associated Vasculitides: Results of the National Needs Assessment Questionnaire. Open Rheumatology Journal, 2015, 9, 16-20.	0.2	7
113	Microscopic polyangiitis and non-HBV polyarteritis nodosa with poor-prognosis factors: 10-year results of the prospective CHUSPAN trial. Clinical and Experimental Rheumatology, 2017, 35 Suppl 103, 176-184.	0.8	7
114	Variations in the clinical practice of physicians managing Takayasu arteritis: a nationwide survey. Open Access Rheumatology: Research and Reviews, 2017, Volume 9, 91-99.	1.6	6
115	Serum periostin as a biomarker in eosinophilic granulomatosis with polyangiitis. PLoS ONE, 2018, 13, e0205768.	2.5	6
116	Feasibility and Construct Validation of the Patient Reported Outcomes Measurement Information System in Systemic Vasculitis. Journal of Rheumatology, 2019, 46, 928-934.	2.0	6
117	Characteristics of Takayasu Arteritis Patients with Severe Ischemic Events. Journal of Rheumatology, 2020, 47, 1224-1228.	2.0	6
118	Ear, nose, and throat involvement in eosinophilic granulomatosis with polyangiitis. Advances in Cellular and Molecular Otolaryngology, 2015, 3, 271-281.	0.4	5
119	Investigational drugs in systemic vasculitis. Expert Opinion on Investigational Drugs, 2017, 26, 1049-1061.	4.1	5
120	Patient Outcomes in Renal-Limited Antineutrophil Cytoplasmic Antibody Vasculitis With Inactive Histology. Kidney International Reports, 2018, 3, 671-676.	0.8	5
121	Advances in the diagnosis of giant cell arteritis. Current Opinion in Ophthalmology, 2019, 30, 407-411.	2.9	5
122	Rituximab versus azathioprine for ANCA-associated vasculitis maintenance therapy: impact on global disability and health-related quality of life. Clinical and Experimental Rheumatology, 2016, 34, S54-9.	0.8	5
123	Cutaneous granulomatous vasculitis and extravascular granulomas. Expert Review of Dermatology, 2006, 1, 315-326.	0.3	4
124	Patient-driven online survey on the clinical manifestations and diagnostic delay of granulomatosis with polyangiitis. Joint Bone Spine, 2016, 83, 599-600.	1.6	4
125	Actualités thérapeutiques de la granulomatose avec polyangite (Wegener) et de la polyangite microscopique. Revue Du Rhumatisme Monographies, 2017, 84, 242-248.	0.0	4
126	Treatment of systemic necrotizing vasculitides: recent advances and important clinical considerations. Expert Review of Clinical Immunology, 2019, 15, 939-949.	3.0	4



#	ARTICLE	IF	CITATIONS
127	Hidradenitis suppurativa and vasculitis: A case series and literature review of a rare association. SAGE Open Medical Case Reports, 2019, 7, 2050313X1988285.	0.3	4
128	Significance of eosinophilia in granulomatosis with polyangiitis: data from the French Vasculitis Study Group Registry. Rheumatology, 2021, , .	1.9	4
129	Developing a composite outcome tool to measure response to treatment in ANCA-associated vasculitis: A mixed methods study from OMERACT 2020. Seminars in Arthritis and Rheumatism, 2021, 51, 1134-1138.	3.4	4
130	Impact of vasculitis on employment and income. Clinical and Experimental Rheumatology, 2018, 36 Suppl 111, 58-64.	0.8	4
131	L38. How to treat primary vasculitis of the central nervous system. Presse Medicale, 2013, 42, 605-607.	1.9	3
132	083.â€fCOMPARISON OF ARTERIAL PATTERNS OF DISEASE IN TAKAYASUâ€™S ARTERITIS AND GIANT CELL ARTERITIS. Rheumatology, 2019, 58, .	1.9	3
133	ANCA status and renal parameters at month 12 post-diagnosis can help predict subsequent relapses in patients with granulomatosis with polyangiitis. Seminars in Arthritis and Rheumatism, 2021, 51, 1011-1015.	3.4	3
134	Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss Syndrome). , 0, , 306-306.		3
135	Efficacy of leflunomide in the treatment of vasculitis. Clinical and Experimental Rheumatology, 2021, 39 Suppl 129, 114-118.	0.8	3
136	Granulomatosis with polyangiitis presenting as pancreatic disease. BMJ Case Reports, 2021, 14, e241033.	0.5	2
137	Cessation of immunosuppressive therapies in patients with Takayasu arteritis with sustained inactive disease. Seminars in Arthritis and Rheumatism, 2022, 52, 151934.	3.4	2
138	Assessment of glucocorticoid tapering in large vessel and anti-neutrophil cytoplasmic antibody-associated vasculitides. Clinical and Experimental Rheumatology, 2021, 39, 119-124.	0.8	2
139	An international Delphi exercise to identify items of importance for measuring response to treatment in ANCA-associated vasculitis. Seminars in Arthritis and Rheumatism, 2022, 55, 152021.	3.4	2
140	Self-Reported Data and Physician-Reported Data in Patients With Eosinophilic Granulomatosis With Polyangiitis: Comparative Analysis. Interactive Journal of Medical Research, 2022, 11, e27273.	1.4	2
141	Polyarteritis nodosa â€œ Challenges and options in management. Indian Journal of Rheumatology, 2015, 10, S64-S71.	0.4	1
142	Reply. Arthritis and Rheumatology, 2018, 70, 151-152.	5.6	1
143	238.â€fEFFICACY OF CONVENTIONAL IMMUNOSUPPRESSANTS IN STEROID-DEPENDENT OR REFRACTORY EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS: STUDY ON A NEW CANADIAN PATIENT COHORT. Rheumatology, 2019, 58, .	1.9	1
144	355.â€fFACTORS PREDICTING SEVERE INFECTIONS IN PATIENTS WITH SYSTEMIC NECROTIZING VASCULITIDES BASED ON DATA FROM 733 PATIENTS ENROLLED IN RANDOMIZEDâ€œCONTROLLED TRIALS. Rheumatology, 2019, 58, .	1.9	1

#	ARTICLE	IF	CITATIONS
145	Vision loss in granulomatosis with polyangiitis: when prednisone is the problem, not the solution. <i>Clinical Rheumatology</i> , 2022, 41, 943-944.	2.2	1
146	Granulomatosis with Polyangiitis. <i>Rare Diseases of the Immune System</i> , 2020, , 97-129.	0.1	1
147	Microscopic polyangiitis and granulomatosis with polyangiitis. , 2019, , 153-172.		1
148	Efficacy of conventional immunosuppressants in relapsing or refractory eosinophilic granulomatosis with polyangiitis: evidence from a Canadian single-centre cohort. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 124, 171-175.	0.8	1
149	Assessment of glucocorticoid tapering in large vessel and anti-neutrophil cytoplasmic antibody-associated vasculitides. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 129, 119-124.	0.8	1
150	Vasculitis research: Don't slow down and plan for a life-time commitment. <i>Presse Medicale</i> , 2015, 44, e221-e222.	1.9	0
151	330. Treatment response criteria for ANCA-associated vasculitis: results of a scoping review. <i>Rheumatology</i> , 2019, 58, .	1.9	0
152	148. Short-form 36 as a measure of health-related quality of life in patients with giant cell arteritis. <i>Rheumatology</i> , 2019, 58, .	1.9	0
153	045. Evaluation of novel serum biomarkers of disease activity in giant cell arteritis, Takayasu arteritis, polyarteritis nodosa, and eosinophilic granulomatosis with polyangiitis. <i>Rheumatology</i> , 2019, 58, .	1.9	0
154	020. Identification of target antigens for anti-endothelial cell antibodies in patients with Takayasu arteritis using proteomics. <i>Rheumatology</i> , 2019, 58, .	1.9	0
155	043. Subglottic stenosis and endobronchial disease in granulomatosis with polyangiitis. <i>Rheumatology</i> , 2019, 58, .	1.9	0
156	035. Candidate biomarkers in ANCA-associated vasculitis identified using a proteomic approach. <i>Rheumatology</i> , 2019, 58, .	1.9	0
157	084. Discovery and validation of a novel angiographic classification scheme in Takayasu arteritis. <i>Rheumatology</i> , 2019, 58, .	1.9	0
158	138. Diffuse alveolar hemorrhage, pulmonary nodules and infiltrates in granulomatosis polyangiitis and microscopic polyangiitis. A cohort study of 736 patients. <i>Rheumatology</i> , 2019, 58, .	1.9	0
159	Editorial. <i>Presse Medicale</i> , 2020, 49, 104040.	1.9	0
160	Update on Maintenance Therapies for ANCA-Associated Vasculitis. <i>Current Treatment Options in Rheumatology</i> , 2021, 7, 112.	1.4	0
161	Facteurs pronostifs des événements cardiovasculaires mortels et non mortels dans la vascularite à ANCA: données de la cohorte Toronto CanVasc. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2021, 88, 279-283.	0.0	0
162	Use of Rituximab for the Treatment of Antineutrophil Cytoplasm Antibody-associated Vasculitis in Canada, 2010-2020. <i>Journal of Rheumatology</i> , 2021, 48, jrheum.210537.	2.0	0

#	ARTICLE	IF	CITATIONS
163	Perinuclear antineutrophil cytoplasmic antibody-associated vasculitis in an elderly woman. Canadian Family Physician, 2016, 62, 635-7.	0.4	0
164	A Tale of 2 Aneurysms. JACC: Case Reports, 2021, 3, 1858-1862.	0.6	0
165	Comments on the giant cell arteritis probability score. Clinical and Experimental Rheumatology, 2019, 37 Suppl 117, 150.	0.8	0
166	Paediatric-to-adult transition experience in vasculitis: report of a model of care and outcomes.. Clinical and Experimental Rheumatology, 2022, , .	0.8	0